134 related articles for article (PubMed ID: 16179864)
1. Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma.
Ilmonen S; Hernberg M; Pyrhönen S; Tarkkanen J; Asko-Seljavaara S
Melanoma Res; 2005 Oct; 15(5):375-81. PubMed ID: 16179864
[TBL] [Abstract][Full Text] [Related]
2. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin.
Vogt T; Zipperer KH; Vogt A; Hölzel D; Landthaler M; Stolz W
Histopathology; 1997 Jan; 30(1):57-63. PubMed ID: 9023558
[TBL] [Abstract][Full Text] [Related]
3. Association of Ki-67, p53, and bcl-2 expression of the primary non-small-cell lung cancer lesion with brain metastatic lesion.
Bubb RS; Komaki R; Hachiya T; Milas I; Ro JY; Langford L; Sawaya R; Putnam JB; Allen P; Cox JD; McDonnell TJ; Brock W; Hong WK; Roth JA; Milas L
Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1216-24. PubMed ID: 12128123
[TBL] [Abstract][Full Text] [Related]
4. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of biomarkers in malignant melanoma.
Hernberg M; Turunen JP; von Boguslawsky K; Muhonen T; Pyrhönen S
Melanoma Res; 1998 Jun; 8(3):283-91. PubMed ID: 9664152
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD40, CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma.
Sviatoha V; Rundgren A; Tani E; Hansson J; Kleina R; Skoog L
Cytopathology; 2002 Feb; 13(1):11-21. PubMed ID: 11985564
[TBL] [Abstract][Full Text] [Related]
9. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma.
Straume O; Sviland L; Akslen LA
Clin Cancer Res; 2000 May; 6(5):1845-53. PubMed ID: 10815907
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma.
Llanos M; Alvarez-Argüelles H; Alemán R; Oramas J; Diaz-Flores L; Batista N
Med Oncol; 2001; 18(1):15-22. PubMed ID: 11778965
[TBL] [Abstract][Full Text] [Related]
11. Association between Ki-67 expression and clinical outcomes among patients with clinically node-negative, thick primary melanoma who underwent nodal staging.
Robinson EM; Rosenbaum BE; Zhang Y; Rogers R; Tchack J; Berman RS; Darvishian F; Osman I; Shapiro RL; Shao Y; Polsky D
J Surg Oncol; 2018 Jul; 118(1):150-156. PubMed ID: 29878361
[TBL] [Abstract][Full Text] [Related]
12. [Expression of P53 protein in cutaneous melanoma].
Casazza S; Gambini C; Tunesi G; Rovida S; Caruso F; Pastorino A; Canepa M
Pathologica; 1993; 85(1097):335-42. PubMed ID: 8233650
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications.
Weiss J; Heine M; Körner B; Pilch H; Jung EG
Br J Dermatol; 1995 Jul; 133(1):23-31. PubMed ID: 7669636
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Chikhlikar PR; Ghosh N; Trivedi TI
Ann Surg Oncol; 2000 May; 7(4):305-11. PubMed ID: 10819372
[TBL] [Abstract][Full Text] [Related]
16. Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome.
Lawrence NF; Hammond MR; Frederick DT; Su Y; Dias-Santagata D; Deng A; Selim MA; Mahalingam M; Flaherty KT; Hoang MP
J Am Acad Dermatol; 2016 Sep; 75(3):595-602. PubMed ID: 27543214
[TBL] [Abstract][Full Text] [Related]
17. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of regulators of cell cycle and apoptosis, p16(INK4a), p53, and bcl-2 in primary mucosal melanomas of the head and neck.
Prasad ML; Patel SG; Shah JP; Hoshaw-Woodard S; Busam KJ
Head Neck Pathol; 2012 Jun; 6(2):184-90. PubMed ID: 22160615
[TBL] [Abstract][Full Text] [Related]
19. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.
Borre M; Stausbol-Gron B; Overgaard J
J Urol; 2000 Sep; 164(3 Pt 1):716-21. PubMed ID: 10953132
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 and p53 expression in head and neck mucosal melanoma: A clinicopathologic analysis of predictors of outcome.
Yin G; Guo W; Liu H; Huang Z; Chen X
Ann Diagn Pathol; 2021 Oct; 54():151789. PubMed ID: 34304143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
